Cetrorelix vs Kisspeptin-10

Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression

Cetrorelix is a synthetic GnRH antagonist peptide used in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges during controlled ovarian stimulation protocols. By competitively blocking GnRH receptors in the pituitary gland, cetrorelix rapidly suppresses LH release without the initial hormonal flare seen with GnRH agonists, allowing more precise timing of oocyte retrieval. Clinical studies including randomized controlled trials have established cetrorelix as an effective option for LH surge prevention in IVF and ICSI cycles, with well-characterized safety and efficacy data across multiple formulations. Cetrorelix is an FDA-approved prescription medication (Cetrotide) indicated for use under specialist supervision in fertility treatment settings. Cetrorelix dosing protocols and IVF context Per FDA labeling (Cetrotide), cetrorelix is available in two protocols for IVF: the multiple-dose protocol (0.25 mg subcutaneously once daily during ovarian stimulation) and the single-dose protocol (3 mg subcutaneously in a single injection). Specific timing, trigger criteria, and supplemental dosing schedules are determined by the treating reproductive endocrinologist per the full FDA prescribing information. Cetrorelix vs ganirelix: Cetrorelix (Cetrotide) and ganirelix (Antagon, Orgalutran) are both GnRH receptor antagonists used in the same IVF indication. Both act as competitive antagonists at the pituitary GnRH receptor, producing rapid suppression without the initial LH flare seen with agonists. They are pharmacologically equivalent in mechanism; differences relate to proprietary formulation, dosing schedule in specific protocols, and market availability in different regions. Neither requires the weeks-long downregulation period that GnRH agonist protocols (triptorelin, leuprolide) involve — antagonist protocols can begin mid-stimulation, reducing the total cycle length. Cetrorelix and ganirelix are both prescription-only fertility medications requiring specialist reproductive endocrinology supervision.

Activates GPR54/KISS1R receptor on GnRH neurons; triggers pulsatile GnRH release → LH/FSH surge → testosterone/estrogen production

Kisspeptin-10 is a 10-amino-acid C-terminal fragment of the KISS1-derived peptide family, which serves as the primary upstream regulator of GnRH pulsatility in the hypothalamus. By binding to the KISS1R receptor on GnRH neurons, kisspeptin-10 triggers GnRH release and downstream LH and FSH secretion, positioning it as a master regulator of the reproductive neuroendocrine axis. Peer-reviewed human studies demonstrate that kisspeptin administration evokes LH pulse generation and modulates gonadotropin secretion in both healthy volunteers and individuals with reproductive dysfunction, including polycystic ovary syndrome. Kisspeptin-10 is an investigational peptide actively studied in clinical research; it is not approved by the FDA for any therapeutic indication and is not available as a licensed pharmaceutical. Kisspeptin-10 research contexts: clinical studies at Imperial College London and other institutions have characterized kisspeptin-10 pharmacology in human subjects across multiple reproductive contexts. In women, kisspeptin administration has been studied for ovulation triggering in IVF protocols as an alternative to hCG, with phase 2 trial data supporting its effectiveness for oocyte maturation while potentially reducing ovarian hyperstimulation syndrome risk. In men with hypogonadotropic hypogonadism, kisspeptin-10 infusion protocols have been studied to characterize LH pulse deficits and assess reproductive axis recovery. The peptide's upstream position in the GnRH axis — above gonadorelin, hCG, and downstream gonadotropins — makes it a research tool for understanding the root causes of hypothalamic-level reproductive dysfunction. Kisspeptin-10 vs kisspeptin-54: the two forms differ in length and pharmacokinetic profile. Kisspeptin-54 is the full 54-amino-acid peptide with a longer half-life in circulation; kisspeptin-10 is the truncated, most biologically active fragment. Human studies have used both forms depending on the research objective — kisspeptin-10 for acute LH pulse characterization, kisspeptin-54 for sustained gonadotropin studies. Neither is commercially available as an approved therapeutic. Fertility-focused telehealth providers and reproductive hormone specialists are listed in the PeptideBase directory.